title: [A case of chemoradiation with tissue expander for local reccurence of rectal cancer].
abstract: The patient was a 64-year-old female who underwent an abdomino-perineal resection for advanced lower rectal carcinoma. The tumor was a mucinous adenocarcinoma, type 2 in the Japanese classification of colorectal carcinoma, and was measured 4.5 cm in size. Histologically, the tumor was considered to be stage II (a2, n1, P0, H0). She received adjuvant chemotherapy with 5-FU/LV. After 7 months from the surgery, the patient developed a hip pain. Pelvic CT scan revealed a 4.5 x 6.0 cm mass anterior to the sacrum. Consequently, a diagnosis of local recurrence with sacrum invasion was made. An operation, involving tissue expander placement in the pelvis and pelvic floor was made by dexon mesh, was performed. Radiotherapy was given to the pelvic region at a total dose of 65 Gy (given 2.5 or 3 Gy each x 25 fragments). Chemotherapy with CPT-11 (100 mg/body) and 5'-DFUR (800 mg/body) was administered for 3 cycles. CEA (ng/ml) was decreased within a normal range from maximum 13.8. No progression was detected on CT, and Hip pain had disappeared. Abscess in the pelvis by tumor necrosis was managed conservatively. In this case, tumor marker is within a normal range over 2 years and QOL was improved, suggesting that chemoradiation with a tissue expander may be effective.
authors.affiliation: Dept. of Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases.
authors.forename: Koji
authors.initials: K
authors.lastname: Tanaka
authors.forename: Shingo
authors.initials: S
authors.lastname: Noura
authors.forename: Masayuki
authors.initials: M
authors.lastname: Ohue
authors.forename: Ko
authors.initials: K
authors.lastname: Takachi
authors.forename: Kentaro
authors.initials: K
authors.lastname: Kishi
authors.forename: Hidetoshi
authors.initials: H
authors.lastname: Eguchi
authors.forename: Terumasa
authors.initials: T
authors.lastname: Yamada
authors.forename: Isao
authors.initials: I
authors.lastname: Miyashiro
authors.forename: Masahiko
authors.initials: M
authors.lastname: Yano
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Ohigashi
authors.forename: Yo
authors.initials: Y
authors.lastname: Sasaki
authors.forename: Osamu
authors.initials: O
authors.lastname: Ishikawa
authors.forename: Shingi
authors.initials: S
authors.lastname: Imaoka
authors.forename: Masao
authors.initials: M
authors.lastname: Kameyama
authors.forename: Kohei
authors.initials: K
authors.lastname: Murata
mesh_terms: D002288:Adenocarcinoma, Mucinous / Q000473:pathology / Q000628:therapy*; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D005260:Female; D005467:Floxuridine / Q000008:administration & dosage; D006801:Humans; D000077146:Irinotecan; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D011788:Quality of Life; D011879:Radiotherapy Dosage; D012004:Rectal Neoplasms / Q000473:pathology / Q000628:therapy*; D015625:Tissue Expansion Devices
chemical_list: D000964:Antimetabolites, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; D005467:Floxuridine; D000077146:Irinotecan; C025034:doxifluridine; D002166:Camptothecin